Insider · CIK 0001612528
Lonnel Coats
director
Files at BPMC (Blueprint Medicines Corp), VERV (Verve Therapeutics, Inc.). First filing Nov 22, 2024, latest Nov 22, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $1.9M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Blueprint Medicines Corp | $1.9M 19,824 shares | -90% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 25, 2025 | VERV Verve Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -136,139 | - | - | 0 | Jul 28, 2025 |
| Jul 25, 2025 | VERV Verve Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -42,200 | - | - | 0 | Jul 28, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Common Stock | -6,144 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -11,818 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,909 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,909 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,875 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,188 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,300 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,300 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,570 | - | - | 0 | Jul 21, 2025 |
| Jun 18, 2025 | BPMC Blueprint Medicines Corp | AGrant or award Common Stock | +3,902 | $12,812.00 | $50M | 6,144 | Jun 24, 2025 |
| Jun 5, 2025 | VERV Verve Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +42,200 | $0.00 | $0 | 42,200 | Jun 6, 2025 |
| Nov 20, 2024 | BPMC Blueprint Medicines Corp | MOption exercise Common Stock10b5-1 | +7,500 | $69.79 | $523k | 20,754 | Nov 22, 2024 |
| Nov 20, 2024 | BPMC Blueprint Medicines Corp | MOption exercise Common Stock10b5-1 | +1,312 | $76.24 | $100k | 22,066 | Nov 22, 2024 |
| Nov 20, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -4,500 | $93.15 | $419k | 17,566 | Nov 22, 2024 |
| Nov 20, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -5,287 | $94.24 | $498k | 12,279 | Nov 22, 2024 |
| Nov 20, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -213 | $94.99 | $20k | 12,066 | Nov 22, 2024 |
| Nov 21, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -9,824 | $94.87 | $932k | 2,242 | Nov 22, 2024 |
| Nov 20, 2024 | BPMC Blueprint Medicines Corp | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 0 | Nov 22, 2024 |
| Nov 20, 2024 | BPMC Blueprint Medicines Corp | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,312 | $0.00 | $0 | 3,188 | Nov 22, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.